ANI PHARMACEUTICALS INC

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $3.9m ($1.1m) $15.5m $6.1m ($22.5m) ($42.6m) ($47.9m) $18.8m ($18.5m) $78.3m
Net Income (Loss) Available to Common Stockholders, Basic $3.9m ($1.1m) $15.3m $6.0m ($22.5m) ($42.8m) ($49.5m) $17.2m ($20.1m) $77.2m
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest ($47.9m) $18.8m ($18.5m) $78.3m
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent $3.9m ($1.1m) $15.5m $6.1m
Depreciation, Depletion and Amortization $22.3m $27.9m $33.7m $44.6m $44.6m $47.3m $59.7m $59.8m $67.7m $91.4m
Depreciation $900k $1.2m $2.1m $4.4m $4.8m $5.5m $7.4m $7.5m $7.4m $8.9m
Amortization of Debt Issuance Costs $844k $845k $1.5m $1.4m $720k $914k $2.4m $2.4m $0
Amortization of Debt Issuance Costs and Discounts $7.3m $7.7m $8.5m $7.0m $1.9m $2.5m $4.0m $3.9m $642k $1.4m
Amortization of Intangible Assets $21.4m $26.7m $31.7m $40.2m $39.9m $41.8m $49.5m $52.3m $60.3m $82.5m
Deferred Income Tax Expense (Benefit) ($9.0m) $3.5m ($5.4m) ($7.3m) ($13.0m) ($16.9m) ($15.2m) ($11.6m) ($23.0m) $11.8m
Share-based Payment Arrangement, Noncash Expense $6.1m $6.1m $6.8m $9.2m $12.9m $10.5m $14.6m $20.7m $29.3m $37.9m
Share-based Payment Arrangement, Expense $6.1m $6.0m $6.7m $9.1m $12.8m $10.4m $14.3m
Goodwill, Impairment Loss $0 $0 $0 $0 $0 $0 $0 $0
Impairment of Intangible Assets, Finite-lived $6.7m $903k $0 $75k $446k $2.4m $112k $0 $3.6m $800k
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) $4.0m $0
Gain (Loss) on Disposition of Assets $0 $0 ($5.3m) ($382k)
Gain (Loss) on Disposition of Intangible Assets $1.8m $750k $0 $0 $382k
Gain (Loss) on Disposition of Other Assets $0 $0 $5.3m ($382k)
Gain (Loss) on Disposition of Property Plant Equipment ($4.6m) ($10.4m) ($5.7m) ($6.6m) ($6.1m) ($2.6m) ($8.9m) ($8.9m) $5.3m ($13.8m)
Gain (Loss) on Extinguishment of Debt $0 $0 ($1.5m) $0 $0 ($7.5m) $0
Income Tax Expense (Benefit) $4.7m $17.4m $4.6m ($2.9m) ($3.4m) ($13.5m) ($14.8m) $1.1m ($3.7m) $17.5m
Other Nonoperating Income (Expense) ($74k) $55k ($550k) ($228k) ($494k) ($4.3m) $670k ($159k) ($4.0m) $1.9m
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable $24.0m $12.9m $4.7m $7.3m $23.7m $5.5m $36.9m ($3.4m) $21.1m $58.5m
Increase (Decrease) in Inventories $1.9m ($5.4m) $379k $7.7m $2.8m ($3.2m) $23.6m $5.8m $21.3m $6.0m
Increase (Decrease) in Accounts Payable $1.1m $3k $3.5m $5.0m ($2.3m) $10.2m $5.0m $7.6m $479k $15.2m
Proceeds from Stock Options Exercised $1.6m $353k $3.0m $5.7m $618k $2.1m $1.5m $9.0m $6.5m $13.6m
Equity Securities, FV-NI, Unrealized Gain (Loss) $0 $0 $6.3m $2.8m
Gain (Loss) Related to Litigation Settlement ($8.8m) $0
Goodwill $1.8m $1.8m $3.6m $3.6m $3.6m $27.9m $28.2m $28.2m $60.0m $62.5m
Net Cash Provided by (Used in) Operating Activities $27.5m $39.4m $67.1m $45.6m $15.3m $3.3m ($31.2m) $119.0m $64.0m $185.2m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $4.6m $10.4m $5.7m $6.6m $6.1m $2.6m $8.9m $8.9m $16.2m $13.8m
Payments to Acquire Businesses, Net of Cash Acquired $16.5m $0 $0 $84.5m $33k $0
Net Cash Provided by (Used in) Investing Activities ($154.1m) ($108.0m) ($27.4m) ($27.5m) ($68.3m) ($105.5m) ($15.7m) ($18.5m) ($404.7m) ($34.3m)
Cash flows from financing activities:
Proceeds from Issuance of Long-term Debt $75.0m $0 $0
Proceeds from Issuance of Common Stock $75.0m $80.6m $0 $0
Payments for Repurchase of Common Stock $2.5m $0 $0 $890k $2.0m $5.0m $11.0m $12.2m
Dividends paid $190k $1.6m $1.6m $1.6m $1.2m
Other Interest and Dividend Income $6.3m $4.9m
Net Cash Provided by (Used in) Financing Activities ($729k) $72.4m ($27.8m) $1.2m ($1.4m) $194.6m ($5.1m) $67.4m $264.9m ($9.9m)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $0 $0 ($470k) ($233k)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $0 $167.9m ($76.2m) $140.7m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $36.1m $48.0m $67.4m $12.9m $105.3m $53.2m $221.1m $144.9m $285.6m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $4.1m $3.8m $6.3m $6.1m $6.9m $9.7m $21.5m $31.4m $24.4m $26.9m
Income Taxes Paid, Net $9.5m $17.8m $6.4m $10.0m $5.0m $10.4m $288k $1.2m $19.1m $17.7m